Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Dr. Nina Wagner-Johnston is Professor of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include non-Hodgkin lymphoma, Hodgkin lymphoma, and HIV-related lymphomas. Dr. Wagner-Johnston serves as the Director for the Lymphoma Drug Development Program at the Johns Hopkins University. Dr. Wagner-Johnston received her baccalaureate degree in nursing from Georgetown University in Washington, DC. She earned her MD and completed her residency training at the University of Chicago, Chicago Illinois. She performed a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Wagner-Johnston joined the Johns Hopkins faculty in 2015. Prior to joining Johns Hopkins, Dr. Wagner-Johnston was an Assistant Professor at Washington University, St. Louis, Missouri. Her research interests include clinical trial and biomarker development for patients with lymphoma. She is additionally involved in palliative/supportive care research and has a particular interest in chemotherapy-induced peripheral neuropathy. Dr. Wagner-Johnston serves as a member on the NCCN Cancer Related Fatigue Guidelines Panel and the ASCO Neuropathy Guidelines Panel. She has served as a journal reviewer for Annals of Oncology, Leukemia and Lymphoma, Blood, and the Journal of Nuclear Medicine. She is a previous recipient of a Young Investigator Award at the Supportive Oncology Conference as well as a Mentoring Program Award through the American Academy of Hospice and Palliative Medicine. She has served on the National Cancer Institute (NCI) Lymphoma Steering Committee Clinical Trials Design Committee and the NCI Symptom Management and Health Related Quality of Life Steering Committee. She is a member of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the AIDS Malignancies Consortium (AMC), and the Eastern Cancer Oncology Group (ECOG) Lymphoma Committee. Dr. Wagner is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Lode J. Swinnen is a cancer specialist in Baltimore caring for patients with lymphoma. Dr. Swinnen received his M.B.Ch.B. degree from the University of Cape Town Medical School. He completed his residency at Presence Saint Joseph Hospital and performed a fellowship in hematology-oncology at Loyola University Stritch School of Medicine. Dr. Swinnen joined the Johns Hopkins faculty in 2002. His research interests include lymphomas and immunodeficiency-associated malignancies. Dr. Swinnen is a member of the Eastern Cooperative Oncology Group and the National Comprehensive Cancer Network. Dr. Swinnen is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

B.S., Massachusetts Institute of Technology M.D., University of Pennsylvania School of Medicine M.B.A., Carey School of Business at Johns Hopkins. Dr. Fuchs is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Myelodysplastic Syndrome (MDS), Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Multiple Myeloma, and Bone Marrow Aspiration.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Chronic B-Cell Leukemia (CBCL).

As an Associate Professor and Director of the Gastrointestinal Program in the Department of Radiation Oncology and Molecular Radiation Sciences at the Johns Hopkins School of Medicine, Dr. Meyer's clinical and research focus is on the treatment of gastrointestinal cancers, including rectal, anal, esophageal, pancreatic, and liver malignancies. He is also leading the effort to establish a liver stereotactic body radiation therapy (SBRT) program within the department. Dr. Meyer has experience with clinical research studies in SBRT, as well as radiation and drug combination therapy for cancer. Make A Gift. Dr. Meyer is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Pancreatic Cancer.

Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

I am a physician-scientist in the Division of Hematological Malignancies and stem cell transplantation at the Sidney Kimmel Comprehensive Cancer Center, where I specialize in the treatment of lymphomas. My primary research focuses on developing new biologic therapies for the treatment of T-cell lymphomas and T-cell leukemias. Dr. Paul is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, and Acute Myeloid Leukemia (AML).

Ravin Garg is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Garg is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Breast Cancer, and Thrombotic Thrombocytopenic Purpura.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as a Distinguished provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

Panayotis Ledakis is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Ledakis is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Appendix Cancer, Desmoplastic Small Round Cell Tumor, Anemia, Colorectal Cancer, and Ureteroscopy. Dr. Ledakis is currently accepting new patients.

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Baer is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Splenectomy. Dr. Baer is currently accepting new patients.

Carole Miller is an Oncologist in Baltimore, Maryland. Dr. Miller is rated as an Advanced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Myeloproliferative Neoplasms (MPN), Philadelphia-Negative Chronic Myeloid Leukemia, and Follicular Lymphoma. Dr. Miller is currently accepting new patients.

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

Christian Okoye is a Radiation Oncologist in Baltimore, Maryland. Dr. Okoye is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Pleuropulmonary Blastoma, Laryngeal Cancer, Breast Cancer, and Angiosarcoma. Dr. Okoye is currently accepting new patients.

Jack Hong is a Hematologist Oncology specialist and a Radiation Oncologist in Baltimore, Maryland. Dr. Hong is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Laryngeal Cancer, Breast Cancer, Pleuropulmonary Blastoma, and Paget Disease of the Breast.

Meredith Wernick is a Radiation Oncologist in Baltimore, Maryland. Dr. Wernick is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Breast Cancer, Pleuropulmonary Blastoma, Familial Prostate Cancer, and Prostate Cancer. Dr. Wernick is currently accepting new patients.

Seung Lee is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Splenectomy.

Aaron Rapoport is a Hematologist in Baltimore, Maryland. Dr. Rapoport is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Rapoport is currently accepting new patients.

Jennie Law is a Hematologist Oncology specialist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Law is rated as an Experienced provider by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin E Disease, and Bone Marrow Aspiration. Dr. Law is currently accepting new patients.